ImmunityBio Inc (NASDAQ:IBRX)’s traded shares stood at 5.69 million during the latest session, with the company’s beta value hitting 0.79. At the last check today, the stock’s price was $3.15, to imply an increase of 3.78% or $0.11 in intraday trading. The IBRX share’s 52-week high remains $10.53, putting it -234.29% down since that peak but still an impressive 27.62% since price per share fell to its 52-week low of $2.28. The company has a valuation of $2.30B, with an average of 6.41 million shares in intraday trading volume over the past 10 days and average of 7.23 million shares over the past 3 months.
Analysts have given a consensus recommendation of Sell for ImmunityBio Inc (IBRX), translating to a mean rating of 1.50. Of 1 analyst(s) looking at the stock, 1 analyst(s) give IBRX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
ImmunityBio Inc (NASDAQ:IBRX) trade information
After registering a 3.78% upside in the latest session, ImmunityBio Inc (IBRX) has traded red over the past five days. The 5-day price performance for the stock is 30.37%, and 3.10% over 30 days. With these gigs, the year-to-date price performance is 23.24%. Short interest in ImmunityBio Inc (NASDAQ:IBRX) saw shorts transact 50.01 million shares and set a 7.44 days time to cover.
The extremes give us $6 and $6 for target low and target high price respectively. As such, IBRX has been trading -90.48% off suggested target high and -90.48% from its likely low.
ImmunityBio Inc (IBRX) estimates and forecasts
Looking at statistics comparing ImmunityBio Inc share performance against respective industry, we note that the company has underperformed competitors. ImmunityBio Inc (IBRX) shares are -47.24% down over the last 6 months, with its year-to-date growth rate lower than industry average at 7.07% against 16.60%. The rating firms project that company’s revenue will grow 3,310.93% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 7.81M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 23.09M.Earnings reports from the last fiscal year show that sales brought in 139k and 40k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 5,516.55% before jumping 57,618.75% in the following quarter.
IBRX Dividends
ImmunityBio Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
ImmunityBio Inc insiders hold 73.49% of total outstanding shares, with institutional holders owning 9.62% of the shares at 36.28% float percentage. In total, 9.62% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 13.83 million shares (or 2.0558% of shares), all amounting to roughly $87.42 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 11.42 million shares, or about 1.6978% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $72.19 million.
We also have Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF as the top two Mutual Funds with the largest holdings of the ImmunityBio Inc (IBRX) shares. Going by data provided on Sep 30, 2024, Vanguard Total Stock Market Index Fund holds roughly 5.72 shares. This is just over 0.82% of the total shares, with a market valuation of $18.01 million. Data from the same date shows that the other fund manager holds a little less at 4.9, or 0.70% of the shares, all valued at about 15.43 million.
